Highlights from the Mectizan Donation Program in 2005
Author Information
Author(s): Mary M Alleman, Nana A Twum-Danso, Björn I Thylefors
Primary Institution: The Mectizan® Donation Program
Conclusion
The Mectizan Donation Program successfully approved over 62 million treatments for onchocerciasis and over 42 million treatments for lymphatic filariasis in 2005.
Supporting Evidence
- In 2005, 62,201,310 treatments of Mectizan for onchocerciasis were approved.
- 42,052,583 treatments of co-administered albendazole and Mectizan were approved for lymphatic filariasis elimination.
- 77% of the treatments for onchocerciasis were for countries in the African Programme for Onchocerciasis Control.
Takeaway
In 2005, a lot of medicine called Mectizan was given to help people with river blindness and another disease called lymphatic filariasis.
Methodology
The program involved mass treatment delivery of Mectizan and albendazole in endemic countries.
Limitations
The expansion of treatment programs was hampered by lack of resources and technical difficulties.
Participant Demographics
The treatments were provided in endemic countries across Africa, Latin America, and Yemen.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website